Expression of bcl-2 - Protein in small cell lung cancer

Lung Cancer

Volumn 15, Issue 1, 1996, Pages 31-40

  Kaiser, U ^a   Schilli, M ^a   Haag, U ^b   Neumann, K ^a   Kreipe, H ^c   Kogan, E ^d   Havemann, K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Bcl 2; Immunohistochemistry; Small cell lung cancer

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTO ONCOGENE; RETROSPECTIVE STUDY;

EID: 0030221312     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-5002(96)00568-5     Document Type: Article

References (26)

1. [1] Ben-Ezra JM, Kornstein MJ, Grimes MM, Krsytal G. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994; 145: 1036-1040.
2. [2] Castle VP, Heidelberger KP, Bromberg J et al. Expression of the apoptosis suppressing protein BCL-2 in neuroblastoma is associated with unfavourable histology and n-myc amplification. Am J Pathol 1993; 143: 1543-1550.
3. [3] Campos L, Rouault JP, Sabido O, Oriol P et al. High expression of bcl-2 protein in acute myeloid leukemia is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
4. [4] Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-7444.
5. [5] Fontanini G. Vignati S, Bigini D, Mussi A et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003-1007.
6. [6] Gasparini G, Barbareschi M, Dogliono C, Palma PD et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995; 1: 189-198.
7. [7] Harris AL. What does bcl-2 mean in solid tumours - friend or foe? Ann Oncol 1994; 5: 388-390.
8. [8] Havemann K, Wolf M, Holle R, Gropp C et al. Alternating versus sequential chemotherapy in small cell lung cancer. Cancer 1987; 59: 1072-1082.
9. [9] Henriksen R, Wilander E, Öberg K. Expression and prognostic significance of bcl-2 in ovarian tumours. Br J Cancer 1995; 72: 1324-1329.
10. [10] Ikegaki N, Katsumatu M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6-8.
11. [11] Jiang, S-X, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995; 177: 135-138.
12. [12] de Jong D, Prins FA, Mason DY, Reed JC et al. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res 1994; 54: 256-260.
13. [13] Koresmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
14. [14] Kreipe H, Alm P, Olsson H, Hauberg M et al. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-Sl. Am J Pathol 1993; 142: 651-657.
15. [15] Le Brun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993; 142: 743-753.
16. [16] Leek RD, Kaklamanis L, Pezella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994; 69: 135-139.
17. [17] Öfner D, Riehemann K, Maier H, Riedmann B et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995; 72: 981-985.
18. [18] Pezzella F, Turley H, Kuzu I, Tungekar MF et al. Bcl-2 protein in non-small cell lung carcinoma. New Engl J Med 1993; 329: 690-694.
19. [19] Reed JC, Kitada S, Takayama S, Miyashita T. Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 1995; 5 (Suppl 1): S61-S65.
20. [20] Sampson SA, Kreipe H, Gillett CE, Smith P et al. KiSl-a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol 1992; 168: 179-185.
21. [21] Schulte-Hermann R, Bursch W, Grasl-Kraupp B. Relevance of apoptosis for carcinogenesis. Verh. Dtsch. Ges. Path. 1994; 78: 15-21.
22. [22] Silvestrini R, Veneroni S, Daidone MG, Benini E et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node - negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
23. [23] van den Oord JJ, Vandeghinste N, de Ley M, de Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
24. [24] Wolf M, Drings P, Hans K, Schroeder M et al. Alternating chemotherapy with adriamycin/ifosfamide/vincristine (AIO) and either cisplatin/etoposide (PE) or carboplatin/etoposide (JE) in small cell lung cancer (SCLC). Lung Cancer 1991; 7 Suppl: 141.
25. [25] Wolf M, Pritsch M, Drings P, Schroeder M et al. Standard vs palliation chemotherapy in metastatic small cell lung cancer: an analysis on treatment efficacy and quality of life. Lung Cancer 1994; 11 Suppl: 92.
26. [26] Wolf M, Havemann K, Hans K, Drings P et al. Treatment intensification with GM-CSF in patients with non-metastatic small cell lung cancer. Onkologie 1995; 18 Suppl 2: 22.